Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. on October 2, 2015. The report discloses management promotions effective October 5, 2015, pursuant to Regulation FD.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements.
Material Changes
The material change disclosed is the appointment of new executive officers:
- Richard M. Mangano, Ph.D. promoted to Chief Scientific Officer.
- Lisa Nolan, Ph.D. promoted to Chief Business Officer.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The information is deemed "furnished" rather than "filed" under the Securities Exchange Act of 1934, and the company states it shall not be deemed an admission as to the materiality of the information solely to satisfy Regulation FD requirements.
Investor Verification Checklist
- Verify the official press release (Exhibit 99.1) for detailed biographies of the new executives.
- Confirm the effective date of the promotions (October 5, 2015).
- Review subsequent filings for any financial impact related to these executive changes.